報價延遲最少15分鐘:2026/09/18 17:17 EDT
盤後時段
|
||||
|
2.7 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.7
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.66/-0.78
|
|
企業價值
429.81M
|
| 資產負債 |
|
每股賬面淨值
0.69
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
40.52M
|
|
每股收益
0.16
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology. |
